ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Moderate Buy” from Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $4.60.

Several equities analysts recently weighed in on the stock. UBS Group assumed coverage on shares of ALX Oncology in a research report on Friday, March 6th. They issued a “buy” rating and a $6.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of ALX Oncology in a research report on Tuesday, March 10th. Wall Street Zen raised shares of ALX Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ALX Oncology in a research report on Wednesday, January 21st. Finally, Piper Sandler raised their price target on shares of ALX Oncology from $3.00 to $4.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th.

Insiders Place Their Bets

In related news, CEO Jason Lettmann sold 12,311 shares of the firm’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $2.17, for a total value of $26,714.87. Following the transaction, the chief executive officer owned 293,609 shares of the company’s stock, valued at approximately $637,131.53. This trade represents a 4.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 21.00% of the company’s stock.

Hedge Funds Weigh In On ALX Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of ALXO. Invesco Ltd. purchased a new position in shares of ALX Oncology in the 1st quarter worth approximately $46,000. Bridgeway Capital Management LLC purchased a new position in shares of ALX Oncology in the 3rd quarter worth approximately $66,000. AQR Capital Management LLC boosted its stake in shares of ALX Oncology by 183.6% in the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock worth $74,000 after buying an additional 77,065 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of ALX Oncology in the 2nd quarter worth approximately $84,000. Finally, Seven Fleet Capital Management LP purchased a new position in shares of ALX Oncology in the 4th quarter worth approximately $133,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $2.03 on Thursday. ALX Oncology has a fifty-two week low of $0.40 and a fifty-two week high of $2.66. The stock has a market cap of $273.16 million, a price-to-earnings ratio of -1.36 and a beta of 0.41. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.07 and a current ratio of 7.21. The firm’s 50-day simple moving average is $1.93 and its 200 day simple moving average is $1.71.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). As a group, research analysts anticipate that ALX Oncology will post -0.66 earnings per share for the current fiscal year.

More ALX Oncology News

Here are the key news stories impacting ALX Oncology this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on ALX Oncology and kept a $4.00 price target, signaling upside potential from current levels.
• Positive Sentiment: The firm raised earnings estimates across several years, including FY2026, FY2027, FY2028, FY2029, and FY2030, which may support investor confidence. HC Wainwright estimate updates for ALX Oncology
• Neutral Sentiment: ALX Oncology remains a loss-making biotech, with HC Wainwright still forecasting negative EPS in every period covered, so the revisions are incremental rather than transformative.
• Negative Sentiment: The company’s most recent reported quarterly EPS missed analyst expectations, which continues to weigh on sentiment around near-term execution.

About ALX Oncology

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.